Regeneron Pharmaceuticals, Inc. $REGN Stake Lessened by Brighton Jones LLC

Brighton Jones LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 571 shares of the biopharmaceutical company’s stock after selling 432 shares during the quarter. Brighton Jones LLC’s holdings in Regeneron Pharmaceuticals were worth $300,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of REGN. Mather Group LLC. increased its holdings in shares of Regeneron Pharmaceuticals by 20.2% in the 1st quarter. Mather Group LLC. now owns 1,090 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 183 shares during the period. Vontobel Holding Ltd. increased its stake in Regeneron Pharmaceuticals by 13.6% in the 1st quarter. Vontobel Holding Ltd. now owns 7,339 shares of the biopharmaceutical company’s stock valued at $4,655,000 after buying an additional 881 shares during the period. Cidel Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 15.7% in the 1st quarter. Cidel Asset Management Inc. now owns 383 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 52 shares in the last quarter. DAVENPORT & Co LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $271,000. Finally, Rossby Financial LCC acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at $87,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $654.04 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The stock has a 50-day simple moving average of $580.56 and a 200 day simple moving average of $564.66. The stock has a market capitalization of $69.32 billion, a PE ratio of 15.66, a P/E/G ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $883.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the company earned $12.46 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Analyst Ratings Changes

REGN has been the subject of several recent research reports. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a research note on Wednesday. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price objective for the company. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. UBS Group reaffirmed a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $813.78.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.